Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: Results from an urban observational cohort
- 129 Downloads
To assess prevalence and risk factors for human immunodeficiency virus (HIV)-related neurocognitive impairment (NCI), the authors performed a 7-year survey in the period 1996 to 2002. A total of 432 patients were examined. HIV-related NCI was diagnosed in 238 patients (55.1%), meeting the HIV dementia (HIV-D) criteria in 45 (10.4%). The prevalence of both NCI and HIV-D did not change significantly during the study period. Compared with patients without NCI, patients with NCI were older (40.4 versus 38.2 years; P = .003), had a higher prevalence of positive HCV serology (61.1% versus 38.9%; P = .003), and a lower nadir CD4 cell count (156 versus 222 cells/μl; P < .001). Compared with patients seen during 1996 to 1999, patients with NCI seen during 2000 to 2002 were older (40.7 versus 38.8 years; P = .004), had a less advanced disease stage (previous acquired immunodeficiency syndrome [AIDS] 28.8% versus 65.7%; P < .001) and a higher nadir CD4 count (174 versus 132 cells/μl; P = .026). This study showed an unchanged prevalence of both HIV-related NCI and HIV-D in the period 1996 to 2002. The authors found evidences for new additional potential risk factors for HIV-related NCI (older age, lower nadir CD4 count, positive hepatitis C virus [HCV] serology), and for a change of risk factors for NCI in the late highly active antiretroviral therapy (HAART) era (older age, less advanced disease, higher nadir CD4 count).
Keywordshighly active antiretroviral therapy HIV dementia HIV infection neurocognitive impairment prevalence
Unable to display preview. Download preview PDF.
- American Academy of Neurology (1991). Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type1 (HIV-1) infection: report of a Woking Group of the American Accademy of Neurol AIDS task Force. Neurology 41: 778–785.Google Scholar
- Justice AC, McGinnis KA, Atkinson JH, Heaton RK, Young C, Sadek J, Madenwald T, Becker JT, Conigliaro J, Brown ST, Rimland D, Crystal S, Simberkoff M, Veterans Aging Cohort 5-Site Study Project Team (2004). Psychiatric and neurocognitive disorders among HIV-positive and negative veterans in care: Veterans Aging Cohort Five-Site Study. AIDS 18(Suppl 1): S49-S59.CrossRefPubMedGoogle Scholar
- Letendre S, Cherner M, Ellis R, Marcotte T, Heaton R, McCutchan JA, Grant I. Individuals coinfected with hepatitis C (HCV) and HIV are more cognitively impaired than those with either virus alone (2002). J NeuroVirol 8(Suppl 1): 27–28.Google Scholar
- Lezak MD (1983). Neuropsychological assessment. New York: Oxford University Press.Google Scholar
- Sidtis JJ, Gatsonis C, Price RW, Singer EJ, Collier AC, Richman DD, Hirsch MS, Schaerf FW, Fischl MA, Kieburtz K, Simpson D, Koch A, Feinberg J, Dafni U, and the AIDS Clinical Trial Group (1993). Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group. Ann Neurol 33: 343–349.CrossRefPubMedGoogle Scholar
- Spinnler H, Tognoni G (1987). Standardizzazione e taratura italiana di test neuropsicologici. Ital J Neurol Sci 6(Suppl 8): 49–54.Google Scholar
- Tozzi V, Balestra P, Galgani S, Murri R, Bellagamba R, Narciso P, Antinori A, Giulianelli M, Tosi G, Costa M, Sampaolesi A, Fantoni M, Noto P, Ippolito G, Wu AW (2003). Neurocognitive performance and quality of life in patients with HIV infection. AIDS Res Hum Retrovirus 19: 643–652.CrossRefGoogle Scholar